(Total Views: 281)
Posted On: 10/27/2017 6:34:27 PM
Post# of 72446
Sure, if you don't mind dying from it.
"The safety profile was consistent with that observed in Phase 2 clinical trials, with no new safety signals detected across the three studies.1-4 In ultIMMa-1 and ultIMMa-2, serious adverse events through week 16 occurred in 2 percent of patients on risankizumab in both studies compared to 3 percent and 1 percent of patients on placebo and 8 percent and 3 percent of patients on ustekinumab, respectively.1,2 Through one year, serious adverse events in the ultIMMa-1 and ultIMMa-2 trials occurred in 8 percent and 7 percent of patients in the continuous risankizumab group, respectively, compared to 11 percent and 7 percent of patients treated continuously with ustekinumab.1,2 In ultIMMa-2, one patient receiving risankizumab died from a sudden cardiac arrest 101 days after the last dose of study drug.2 A second patient receiving risankizumab died 161 days after the last dose, with cause of death unknown.2 Both patients had a past history of cardiovascular risk factors.2 There were no deaths in ultIMMa-1.1"
Biologics are known to have superior efficacy than oral drugs, but Otezla still had $1B in sales despite having inferior efficacy. I think P's main comparator is Otezla, not biologics.
"The safety profile was consistent with that observed in Phase 2 clinical trials, with no new safety signals detected across the three studies.1-4 In ultIMMa-1 and ultIMMa-2, serious adverse events through week 16 occurred in 2 percent of patients on risankizumab in both studies compared to 3 percent and 1 percent of patients on placebo and 8 percent and 3 percent of patients on ustekinumab, respectively.1,2 Through one year, serious adverse events in the ultIMMa-1 and ultIMMa-2 trials occurred in 8 percent and 7 percent of patients in the continuous risankizumab group, respectively, compared to 11 percent and 7 percent of patients treated continuously with ustekinumab.1,2 In ultIMMa-2, one patient receiving risankizumab died from a sudden cardiac arrest 101 days after the last dose of study drug.2 A second patient receiving risankizumab died 161 days after the last dose, with cause of death unknown.2 Both patients had a past history of cardiovascular risk factors.2 There were no deaths in ultIMMa-1.1"
Biologics are known to have superior efficacy than oral drugs, but Otezla still had $1B in sales despite having inferior efficacy. I think P's main comparator is Otezla, not biologics.
Quote:
Looks like Abbvie has the new gold standard of biologics for Psoriasis.
(2)
(0)
